ABSTRACT
Human P-glycoprotein (Pgp) confers resistance to various structurally unrelated chemotherapeutic and cytotoxic agents (1, 2) . Resistance results from the ability of Pgp to function as an ATP-dependent efflux pump for drug molecules (3, 4) . Structurally, Pgp is a 1,280-amino acid integral membrane phospho-glycoprotein with two homologous halves connected by a short stretch of linker region (5) . Each half consists of six putative transmembrane (TM) domains followed by a consensus nucleotide binding domain (5) . Both of the ATP binding sites are catalytically active (6) and are required for the protein to function as a transporter (7) . Pgp in isolated membranes (8) as well as in purified and reconstituted form (9) exhibits intrinsic ATPase activity that is stimulated upon interaction with the drug substrates. Besides substrate molecules, Pgp is also known to interact with a battery of chemical compounds, collectively known as reversing agents, that inhibit its ability to extrude anticancer drugs (1) . These reversing agents, some of which are believed to be transport substrates by themselves, are also diverse in their chemical composition.
The mechanism by which Pgp recognizes and translocates such a broad spectrum of chemical compounds is presently unclear. Changes in single amino acid residues have been reported throughout the linear sequence of the Pgp molecule that resulted in alteration of the substrate specificity and drug-resistance profile (10) (11) (12) (13) (14) (15) . It is yet to be determined whether these residues directly take part in substrate recognition by forming contact sites for the drug molecules, or their change indirectly affects substrate interaction through a change in the overall structure of the protein.
To map the major areas of contact for the substrates within Pgp, photoaffinity analogs of various drugs have been used (16) (17) (18) (19) . Independent studies with Pgp involving different drug analogs have identified two major regions of photoaffinity labeling, one within each half of the protein (20) (21) (22) . In the linear sequence of Pgp they correspond to areas in and around the putative TMs 5 and 6 in the N-terminal half, and TMs 11 and 12 in the C-terminal half (22, 23) . Site-directed mutagenesis and domain-swapping experiments have also emphasized the role of these two regions in determining substrate specificity of Pgp (ref. 24 ; C. A. Hrycyna, P. Wu, U. A. Germann, I.P., and M.M.G., unpublished data). However, a major question that remains unanswered is whether the covalent binding regions identified in each half of Pgp are part of a single drug binding site or whether they represent two independent drug-interaction domains. Data regarding the number of drug-interaction sites within Pgp and their spatial arrangement within the drug-translocating pathway are essential to understand the mechanism of action of Pgp.
In this study using a photoaffinity substrate analog,
, and a known modulator of Pgp function, cis(Z)-flupentixol, we provide direct evidence in favor of two nonidentical drug-interaction sites within Pgp and propose a model for the role of these two sites in drug translocation.
DMEM with 10% fetal bovine serum as described (27) . The recombinant baculovirus carrying either the human MDR1 gene, with 6ϫ His-tag at the C-terminal end, BV-MDR1(H 6 ) (M.R., S.V.A., D. Chen, C. A. Hrycyna, S.D., M.M.G., and I.P., unpublished data), or the MDR2 gene, BV-MDR2 (provided by U. A. Germann, Vortex Pharmaceuticals, Cambridge, MA) were used to infect High Five insect cells grown in serum free Ex-cell 400 medium as described (28) . Cells were grown at 27°C in monolayer to confluency, infected with the recombinant baculovirus with multiplicity of infection of 10, and harvested 3 days postinfection.
Preparation of Crude Membranes from Insect Cells. Infected cells were scraped off and washed two times in PBS containing 1% aprotinin and incubated on ice for 45 min in lysis buffer (50 mM Tris⅐HCl, pH 7.5͞50 mM mannitol͞2 mM EGTA͞1 mM DTT͞1 mM 4-(aminoethyl)benzenesulfonyl fluoride (AEBSF)͞1% aprotinin). Cells were disrupted by repeated strokes of a Dounce homogenizer. Following lysis, undisrupted cells and nuclei were removed by centrifugation at 500 ϫ g for 12 min. The supernatant was diluted with resuspension buffer containing 50 mM Tris (pH 7.5), 300 mM mannitol, 1 mM EGTA, 1 mM DTT, 1 mM AEBSF, and 1% aprotinin and centrifuged at 100,000 ϫ g for 1 h. After washing once with the same buffer, the pellet was resuspended in resuspension buffer containing 10% glycerol by passing through a hypodermic needle (gauge size 19 and then 23) and stored at Ϫ70°C. Protein content was determined by a modified Lowry method (29) using BSA as a standard.
Bodipy FL-Prazosin Accumulation Assay. Cells were harvested by trypsinization, washed, and resuspended in Iscove's modified Eagle's medium (IMEM) supplemented with 5% fetal bovine serum. To determine steady-state accumulation of Bodipy FLprazosin, 5 ϫ 10 6 cells were incubated in 5 ml of IMEM (prewarmed to 37°C) containing 5% fetal bovine serum and 0.5 M Bodipy FL-prazosin, with or without 10 M of cyclosporin A for 40 min at 37°C. Following incubation, cells were centrifuged at 500 ϫ g for 5 min, resuspended in 300 l PBS containing 0.1% BSA, and analyzed with a FACSort flow cytometer equipped with CELL QUEST software (Becton Dickinson).
Measurement of ATPase Activity. Pgp-associated ATP hydrolysis was measured by determining the release of inorganic phosphate from MgATP in the presence and absence of 0.3 mM sodium orthovanadate using a colorimetric assay as described by Sarkadi et al. (8) , with minor modifications.
Photoaffinity Labeling with [ 125 I]IAAP. Photoaffinity labeling of crude membranes was carried out according to Bruggemann et al. (20) , with slight modifications. An aliquot of membranes (10 g protein) was incubated for 10 min with indicated concentrations of [ 125 I]IAAP at room temperature in 10 mM Tris⅐HCl (pH 7.5), 50 mM NaCl, 300 mM mannitol, and 1% aprotinin (labeling buffer) under subdued light. Following incubation, membranes were illuminated with a UV lamp (General Electric no. F15T8-BLB; 366 nm) for 10 min at room temperature. The 5ϫ SDS͞PAGE sample buffer was added to the reaction mixture and kept at 21-23°C for another 30 min before analyzing by SDS͞PAGE. Where appropriate, membranes were pre-incubated for 3-5 min with substrates or modulators of Pgp before the addition of [ 125 I]IAAP.
Quantitation of Radioactivity in Protein Bands. Gels were fixed with a solution containing 30% methanol and 10% acetic acid for 15 min, treated with Novex gel drying solution for 10 min, and air dried between Dryease mini-cellophane for 16-18 h. Dried gels were exposed to Kodak Biomax-MR X-ray films at Ϫ80°C. The radioactive bands were cut out from the gel and soaked in 1 ml of tissue solubilizer (Solvable) from Packard at room temperature for 16 h and then diluted to 15 ml with Biosafe II scintillation fluid. Radioactivity associated with each band was determined in a scintillation counter.
Trypsin Digestion of Pgp Containing Membranes. To generate the N-and C-terminal halves of Pgp, membranes were incubated at 37°C with 0.75-1.5ϫ trypsin (by weight) for 15 min. Reactions were stopped by addition of 5-fold excess of soybean trypsin inhibitor followed by SDS͞PAGE sample buffer. Samples were subjected to separation by SDS͞PAGE using 8% gel, and the photolabeled fragments were detected by autoradiography.
SDS͞PAGE and Immunoblot Analysis. Electrophoresis and immunoblot analysis were performed as described (30) . (33) , in plasma membrane preparations (Fig. 1C, autoradiogram) , and in reconstituted proteoliposomes (unpublished data). Prior studies using photoaffinity analogs of different drug molecules demonstrated the presence of two major photolabeled regions, one on each half of the protein (20) (21) (22) . These two areas included TMs 5 and 6 in the N-terminal half and TMs 11 and 12 in the C-terminal half of Pgp (22, 23) .
RESULTS

Prazosin and Its
To determine the effect of cis(Z)-flupentixol on [ 125 I]IAAP labeling of each of these two halves, we have taken advantage of a highly susceptible trypsin cleavage site in the linker region between the two halves of Pgp (20, 34) . Incubation of insect cell membranes with trypsin, in a protein to trypsin ratio of 1:0.75-1.5 (wt͞wt), allowed separation of the two halves by SDS͞PAGE. In an 8% gel, the N-and C-terminal halves of the protein were detected as 70-and 60-kDa bands, respectively (Fig. 2A) . Identity of the two halves was determined by immunoblot analysis using polyclonal antibodies PEPG 13 and 4007 [specific for the N-and C-terminal half, respectively (31, 35) ; Fig. 2B ]. An additional band of 65 kDa was also photolabeled but was not detected by antibodies against Pgp. Labeling of this endogenous insect cell membrane protein was not inhibited by vinblastine or cyclosporin A (see Fig. 4 ).
A total of 5 nM [ 125 I]IAAP labeled both N-and C-terminal halves. Radioactivity associated with the C-terminal half was about 1.5-to 2-fold higher than that of the N-terminal half. However, incubation of the membranes with cis(Z)-flupentixol for 3 min at 21-23°C before addition of 5 nM [ 125 I]IAAP dramatically enhanced labeling of the C-terminal half of the protein without any significant effect on the N-terminal half (Fig.  2 A) . The total radioactivity associated with the two major bands and undigested Pgp equals the amount associated with the intact Pgp molecule before digestion (data not shown). For convenience, we named the [ 125 I]IAAP binding site that photoaffinity labeled the N-terminal half, the N-site, and the one that photoaffinity labeled the C-terminal half, the C-site. However, this does not imply that the sites are exclusively formed by the respective halves. Photoaffinity-labeled membranes were incubated with 7.5 g of trypsin as described. A total of 2 g of each sample were run on a 8% SDS͞PAGE, dried, and exposed to x-ray film. (B) The identity of the two halves of the Pgp molecule was determined by immunoblot analysis using polyclonal antibodies PEPG 13 and 4007, specific for the N-and C-terminal halves of Pgp, respectively. The arrow with long tail, the arrowhead with short tail, and the arrowhead show the position of Pgp, N-half, and C-half, respectively. (Fig. 5A ). The inhibition was concentration-dependent, with a significant drop in labeling observed at 50 M vanadate, the lowest concentration used in the experiment. When radioactivity associated with N-and C-sites was estimated, a clear difference in the extent of inhibition was observed between them. At 400 M vanadate, the C-site retained only 10% of the [ 125 I]IAAP that was bound in the absence of vanadate, whereas the N-site retained 35-45% of the binding. At this concentration vanadate completely inhibited Pgp-mediated ATP hydrolysis (data not shown). This result suggests a differential susceptibility of the two sites to MgADP⅐V i induced conformational change in Pgp. No inhibition was evident when ATP was excluded from the reaction (Fig. 5A) (Fig. 5B) . Therefore, the effect of vanadate-induced inhibition on the C-site was far more profound than on the N-site. These data also indicate that the N-and C-sites represented different [
125 I]IAAP interaction sites.
DISCUSSION
The unusually broad range of substrate specificity of human Pgp has stimulated interest in elucidating its underlying mechanism of drug recognition. A major step toward achieving this goal will be determining the number of substrate-interacting sites within the protein molecule. Over the years photoaffinity labeling has emerged as a powerful technique to study substrate and ligand binding properties of transporters and receptor proteins. Independent studies, using different photoaffinity analog of Pgp substrates, successfully detected two proteolytic fragments, one from each half of Pgp as major photoaffinity labeled sites (20, 22, 23, 39) . Competition studies also suggested the presence of more than one drug binding site (40) . However, no study until now has conclusively answered the question whether the two photolabeled peptides are part of a common drug binding site or whether they represent two separate drug-interaction domains. In this work we show that there are at least two distinguishable drug-interaction sites of Pgp.
To study this question we made use of the photoaffinity compound, [ 125 I]IAAP, which is a derivative of the ␣ 1 -adrenoreceptor antagonist prazosin. Both prazosin and its fluorescent analog, Bodipy FL-prazosin, are substrates of Pgp (Fig. 1  A and B) . The photoaffinity analog, [ 125 I]IAAP, specifically labels Pgp but not the MDR2 gene product, which is closely related but functions as a phosphatidylcholine translocase (ref. 41 ; Fig. 1C  Left) . We photoaffinity labeled the intact Pgp molecule and then, taking advantage of a highly susceptible trypsin cleavage site in the linker region, separated the two halves by SDS͞PAGE (Fig.  2) . The total [ 125 I]IAAP bound to the intact Pgp molecule was distributed in a ratio of 2:3 between the N-and C-terminal halves, respectively, which was in close agreement with previous studies using [ 3 ]IAAP labeling of the two halves was studied, we found an 8-to 10-fold increase in photoaffinity labeling of the C-site without any significant change in the extent of labeling of the N-site (Fig. 2 A) . This preferential increase in binding was due to enhanced affinity of the C-site for (Fig. 3) . This result clearly suggests that photoaffinity labeling of the two halves represents two separate events of drug-interaction rather than two covalent attachment sites for the photoactive derivative within a single site.
It is worth pointing out that the terms N-site and C-site do not imply that the drug binding regions are exclusively formed by the N-and C-terminal halves, respectively. Two homologous halves of the human Pgp have been expressed separately in insect cells (42) . Although both halves have low ATPase activity, neither of them exhibited drug-stimulated ATP hydrolysis, indicating a lack of proper interaction with drug substrates. When the half molecules were coexpressed, the drug-stimulated ATPase activity was recovered to a certain extent. Therefore, to achieve a functionally significant interaction with the substrate molecule, proper association between the two halves is necessary. We speculate that the photolabeled residues are located in two different halves of the protein with respect to its linear amino acid sequence, but that both halves come close together to form a drug translocating pathway within which N-site and C-site are spatially distinct substrate interaction pockets. This model is also supported by the evidence that mutations in the N-terminal TM 6 abrogate the ability of cis(Z)-flupentixol to stimulate labeling of the C-site (C. A. Hrycyna, S.D., S.V.A., I.P., and M.M.G., unpublished data).
Urbatsch et al. (37) proposed that inhibition of ATP hydrolysis by vanadate occurs through trapping of MgADP⅐V i , a stable analog of MgADP⅐P i , in the catalytic site of Pgp. Based on the reduction in the level of (Fig. 5) , we found that the C-site, to which binding was stimulated by cis(Z)-flupentixol, retained only 10-13% of its binding after vanadate treatment, whereas the N-site showed 40-45% residual binding. These data indicate a difference in coupling between the N and C drug-interaction sites and the catalytic domains, further emphasizing that these are distinct sites.
Based on these results and other studies, we propose a model on possible roles for the two nonidentical [ 125 I]IAAP binding sites in the event of drug translocation (Fig. 6) . This model is an extension of the catalytic scheme for ATP hydrolysis by Pgp originally proposed by Senior et al. (36) . We suggest that the TM domains come close to each other and contribute to the formation of two spatially distinct substrate interaction sites, both of which are part of the drug-translating pathway. The C-site, to which [ 125 I]IAAP binding was stimulated by cis(Z)-flupentixol and which is more sensitive to vanadate-trapping, represents the initial drug-recognition site, or the ON-site (Fig. 6 ). This site is closer to the cytosolic phase of the membrane to recruit drug molecules (D) from the cytosol or from the inner leaflet of the lipid bilayer. The N-site, which was insensitive to cis(Z)-flupentixol and relatively less sensitive to vanadate trapping, functions as the OFF-site from which the drug molecule is finally released to the exterior. The ON-and OFF-sites are functionally equivalent to the inside-facing aspect and outside-facing aspect of the drug binding site proposed by Senior et al. (36) . Movement of the drug substrate from the ON-site to the OFF-site is unfavorable and rate-limiting for the drug to be translocated, but can be driven by the large free energy change that occurs during ATP hydrolysis (Fig. 6 ). This change involves generation of MgADP⅐P i at the catalytic site and conversion of the ON-site to a low affinity site favoring movement of the drug molecule to the OFF-site. Once it is in the OFF-site, the drug molecule is released to the exterior. The release of drug from the OFF-site either precedes or takes place simultaneously with the release of P i . This conformation of Pgp (Pgp⅐MgADP⅐P i ) with low affinity for substrate can be stabilized by trapping MgADP⅐V i at the MgADP⅐P i site (Fig. 6, IV A) . The relatively passive nature of the OFF site (with lower affinity for substrate) is consistent with a single K m for the stimulation of ATP hydrolysis by substrates (9, 36) .
We propose that cis(Z)-flupentixol interacts with an allosteric site of Pgp (unpublished data), which favors binding of the substrate to the ON-site by inhibiting translocation to the OFF-site. This allosteric site might overlap with either the ON or OFF-sites or be distinct. The identification of amino acid residue(s) cross-linked with [ 125 I]IAAP and directed mutagenesis of these residues should help to elucidate the druginteraction sites on Pgp. 
